The Expression of Serum Angiogenesis Marker in Patients Presenting With Hemoptysis

Samsung Medical Center

Status: Completed

Conditions: Hemoptysis; Inflammatory Lung Diseases

Study type: Observational

Funder types: Other

Identifiers

NCT01171768

2008-05-043

Details and patient eligibility

About

Vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) are major mediators of angiogenesis and are induced by tissue inflammation and hypoxia. While elevated serum VEGF levels have been reported in inflammatory lung diseases, especially with hemoptysis, there was no study to evaluate the Ang-2 levels in lung inflammatory diseases according to the presence of hemoptysis, inflammatory biomarker and hypoxia.

Enrollment: 52 estimated patients

Sex: All

Ages: 20 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients visited Samsung Medical Center for the treatment of benign inflammatory disease such as bronchiectasis, aspergilloma, pneumonia and post-tuberculosis destroyed lung

Exclusion criteria

• patients with tumorous condition including lung cancer, vasculitis and the lung disease associated with collagen vascular disease on the point of enrollment

Trial design

52 participants in 2 patient groups

patients with hemoptysis within 2 weeks

patients without hemoptysis within 2 years